201. Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer
- Author
-
Yongqi Zhen, Xiaoxi Zeng, Yanmei Chen, Lan Zhang, Lixia Chen, Zijian Yang, Yu-Shang Yang, Dejuan Sun, and Yong Yuan
- Subjects
Antineoplastic Agents ,Apoptosis ,01 natural sciences ,03 medical and health sciences ,Structure-Activity Relationship ,Carcinoma, Non-Small-Cell Lung ,Catalytic Domain ,Cell Line, Tumor ,Drug Discovery ,medicine ,Autophagy ,Autophagy-Related Protein-1 Homolog ,Humans ,Lung cancer ,030304 developmental biology ,Cell Proliferation ,Pharmacology ,A549 cell ,0303 health sciences ,Molecular Structure ,010405 organic chemistry ,Kinase ,Chemistry ,Organic Chemistry ,Intracellular Signaling Peptides and Proteins ,General Medicine ,ULK1 ,medicine.disease ,0104 chemical sciences ,Molecular Docking Simulation ,Pyrimidines ,Docking (molecular) ,Drug Design ,Cancer research ,Pharmacophore ,Drug Screening Assays, Antitumor ,Protein Binding - Abstract
UNC51-like kinase1 (ULK1) recruits its binding partners and initiates the autophagy process in cancer. ULK1 is significantly overexpressed in Non-small cell lung cancer (NSCLC) and negatively correlated with clinical prognosis in NSCLC patients. Based upon the binding features of ULK1, we explored the pharmacophore modeling to discover the common anchoring features. It was verified by synthesizing 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives, as well as subsequently elucidating the structure-activity relationships (SAR). Among all the obtained ULK1 inhibitors, 5-bromo-4-(2-fluoro-4-nitrophenoxy)-N-(3,4,5-trimethoxyphenyl) pyrimidin-2-amine (3s), was the most active one. The docking analysis was conducted to compare 3s and SBI-0206965, which further elucidated the roles of the H-bond donor. This compound inhibited the proliferation of A549 cells and showed strong inhibitory activity against ULK1 kinase. Moreover, we found that compound 3s could induce apoptosis while simultaneously blocking autophagy. Collectively, these findings shed new light on compound 3s that would be utilized as a promising candidate drug for the future NSCLC therapy.
- Published
- 2020